ALSO NOTED: Generics cheaper in US; J&J panel surprisingly independent; and much more...

> Lured by Canada's reputation for cheaper medicines, many Americans have been paying a premium for generic drugs that can actually be cheaper in the US. Story

> The New York Times examines the fiercely independent work of a panel of experts Johnson & Johnson assembled to look into safety concerns involving Natrecor. Article

> Chutes & Ladders: Dr. Rahul Singhvi has been named president and CEO of Novavax. Release

> Executives at Altea Therapeutics in Atlanta are finding it hard to locate the kind of facilities needed by a growing biotech company. Story

> DOV Pharmaceutical of Hackensack, New Jersey, has amended its deal with Merck regarding novel antidepressants. Release

> Germany's Cenix BioSciences says it has delivered a collection of potential new drug targets to Bayer HealthCare. Release

> New River Pharmaceutical of Radford, Virginia, says it has reprioritized its preclinical drug candidates in a pipeline review. Release

> Alexion Pharmaceuticals and Procter & Gamble Pharmaceuticals have completed enrollment of a Phase III trial of a PRIMO-CABG2 efficacy trial of pexelizumab. Release

And Finally… Is the rising rate of melanoma the result of an epidemic, or is the rapid spread of screening really behind the scary surge? Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.